AnalystRatingsNetwork.com has reported that the shares of Gilead Sciences have been given an average recommendation of ‘Buy’ by the twenty-six brokerages that were presently covering the company.

The stock has been rated with a sell recommendation by one of the equities research analyst, while two have issued a hold recommendation, twenty have issued a buy recommendation and two have assigned a strong buy recommendation to the company.

The average 12-month price target among brokerages that issued ratings on the stock in the previous year was $122.67.

Recently many analysts have weighed in on GILD shares. In a research note on Friday, the analysts at Bank of America have reiterated an ‘underperform’ rating on shares of Gilead Sciences.

In a research note on Thursday, analysts at Morgan Stanley have reiterated an ‘overweight’ rating and set a $109.00 price target on shares of Gilead Sciences. Analysts at Barclays have also reiterated an ‘overweight’ rating. They have set a $125.00 price target on shares of Gilead Sciences in a research note on Thursday.

At last, the analysts at BMO Capital Markets have reiterated an ‘outperform’ rating by setting a $159.00 price target on shares of Gilead Sciences in a research note on Thursday.

On Tuesday, Gilead Sciences traded up 1.31% by hitting $105.21. The stock had a trading volume of 5,762,718 shares.

Gilead Sciences has shown a 52-week low of $78.50 and a 52-week high of $116.83. The stock’s 50-day moving average was $101, whereas its 200-day moving average was $102. The company is having a market cap of $156.70 billion and a P/E ratio of 14.31.

Gilead Sciences has last announced its earnings results on Thursday, April 30th. For the quarter, the company has reported $2.94 EPS and has beaten the Thomson Reuters consensus estimate of $2.32 by $0.62. The company had revenue of $7.59 billion for the quarter, as compared to the consensus estimate of $6.81 billion.